Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria-Reference-Cited by-同舟云学术

Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria

Published:2018-07-20 Issue:4 Volume:39 Page:299-304
ISSN:1088-5412
Container-title:Allergy and Asthma Proceedings
language:en
Short-container-title:allergy asthma proc

Author:

Sologuren Ander¹,Viñas Rosa²,Cordón Esther³,Riesgo Susana E.²,del Mar Forés María²,Senán María Rosa⁴,Fernández Sonia¹,Labeaga Luis⁵,Ruiz-Miján Manuel¹

Affiliation:

1. From the Pharmacovigilance Unit, Faes Farma S. A., Leioa-Bizkaia, Spain

2. Centre d'Atenció Primaria Amadeu Torner, Barcelona, Spain

3. Centro de Salud Los Cármenes, Madrid, Spain

4. Centre d'Atenció Primaria El Clot, Barcelona, Spain

5. Medical Department, Faes Farma S. A., Leioa-Bizkaia, Spain

Publisher

Oceanside Publications Inc.

Subject

Pulmonary and Respiratory Medicine,General Medicine,Immunology and Allergy

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options;Expert Review of Clinical Immunology;2023-05-24

2. Bilastine 0.6% preservative-free eye drops, a once-daily treatment for allergic conjunctivitis;Journal of Investigational Allergology and Clinical Immunology;2023-02-21

3. Expert opinion on the role of bilastine and bilastine-montelukast combination in the management of allergic rhinitis: An Indian perspective;The Journal of Association of Chest Physicians;2023

4. Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia;Drugs in Context;2022-03-15

5. Efficacy of once-daily ophthalmic bilastine for the treatment of allergic conjunctivitis: a dose-finding study;Journal of Investigational Allergy and Clinical Immunology;2022-03-01